Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$29.83 -1.3%	$23.74	$20.39 ▼ $53.96	$1.39B	0.76	629,370 shs	651,991 shs
LRMR Larimar Therapeutics	$4.01 -5.9%	$3.29	$1.61 ▼ $9.50	$331.94M	0.93	1.73 million shs	1.88 million shs
NTLA Intellia Therapeutics	$10.99 +0.8%	$10.88	$5.90 ▼ $24.16	$1.18B	2.31	5.20 million shs	4.76 million shs
PAHC Phibro Animal Health	$30.67 +0.3%	$27.57	$16.16 ▼ $31.80	$1.24B	0.8	257,544 shs	316,304 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	0.00%	+25.28%	+37.47%	+19.99%	-29.71%
LRMR Larimar Therapeutics	0.00%	+12.01%	+20.78%	+102.53%	-47.03%
NTLA Intellia Therapeutics	0.00%	+1.85%	-7.10%	+29.29%	-48.91%
PAHC Phibro Animal Health	0.00%	+9.15%	+3.16%	+27.79%	+76.37%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMPH Amphastar Pharmaceuticals	3.1975 of 5 stars	1.3	1.0	0.0	3.7	2.5	4.2	1.3
LRMR Larimar Therapeutics	2.4894 of 5 stars	3.6	1.0	0.0	0.0	3.0	3.3	0.0
NTLA Intellia Therapeutics	4.5134 of 5 stars	4.3	1.0	0.0	4.7	3.0	2.5	0.6
PAHC Phibro Animal Health	3.593 of 5 stars	0.9	2.0	2.5	1.1	2.8	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMPH Amphastar Pharmaceuticals	2.50	Moderate Buy	$31.50	5.60% Upside
LRMR Larimar Therapeutics	3.10	Buy	$18.43	359.57% Upside
NTLA Intellia Therapeutics	2.58	Moderate Buy	$29.05	164.36% Upside
PAHC Phibro Animal Health	1.83	Reduce	$24.40	-20.44% Downside

Current Analyst Ratings Breakdown

Latest LRMR, PAHC, NTLA, and AMPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	LRMR Larimar Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$22.00 ➝ $18.00
8/13/2025	NTLA Intellia Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
8/12/2025	AMPH Amphastar Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$36.00
8/11/2025	NTLA Intellia Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$68.00 ➝ $60.00
8/8/2025	NTLA Intellia Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$50.00 ➝ $45.00
8/8/2025	AMPH Amphastar Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$30.00 ➝ $25.00
8/8/2025	NTLA Intellia Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$25.00 ➝ $21.00
8/8/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $25.00
7/7/2025	PAHC Phibro Animal Health	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$25.00 ➝ $35.00
6/25/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$21.00 ➝ $26.00
6/24/2025	LRMR Larimar Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMPH Amphastar Pharmaceuticals	$731.97M	1.89	$5.01 per share	5.96	$16.29 per share	1.83
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$2.69 per share	N/A
NTLA Intellia Therapeutics	$57.88M	20.38	N/A	N/A	$6.66 per share	1.65
PAHC Phibro Animal Health	$1.02B	1.22	$2.11 per share	14.51	$6.34 per share	4.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMPH Amphastar Pharmaceuticals	$159.52M	$2.67	11.17	9.07	N/A	18.64%	20.76%	9.68%	11/5/2025 (Estimated)
LRMR Larimar Therapeutics	-$80.60M	-$1.56	N/A	N/A	N/A	N/A	-58.19%	-50.79%	8/20/2025 (Estimated)
NTLA Intellia Therapeutics	-$519.02M	-$4.69	N/A	N/A	N/A	-908.48%	-57.48%	-45.04%	N/A
PAHC Phibro Animal Health	$2.42M	$0.78	39.32	14.60	0.51	2.68%	30.51%	6.89%	8/27/2025 (Estimated)

Latest LRMR, PAHC, NTLA, and AMPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/27/2025	Q4 2025	PAHC Phibro Animal Health	$0.52	N/A	N/A	N/A	$362.24 million	N/A
8/14/2025	Q2 2025	LRMR Larimar Therapeutics	-$0.47	-$0.41	+$0.06	-$0.41	N/A	N/A
8/7/2025	Q2 2025	NTLA Intellia Therapeutics	-$1.03	-$0.99	+$0.04	-$0.98	$12.26 million	$14.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	1.57%	N/A	61.54%	N/A

Latest LRMR, PAHC, NTLA, and AMPH Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/29/2025	PAHC Phibro Animal Health	quarterly	$0.12	1.71%	9/3/2025	9/3/2025	9/24/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMPH Amphastar Pharmaceuticals	0.80	3.29	2.21
LRMR Larimar Therapeutics	N/A	7.48	7.48
NTLA Intellia Therapeutics	N/A	5.19	4.90
PAHC Phibro Animal Health	2.67	2.91	1.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMPH Amphastar Pharmaceuticals	65.09%
LRMR Larimar Therapeutics	91.92%
NTLA Intellia Therapeutics	88.77%
PAHC Phibro Animal Health	99.34%

Insider Ownership

Company	Insider Ownership
AMPH Amphastar Pharmaceuticals	27.50%
LRMR Larimar Therapeutics	4.50%
NTLA Intellia Therapeutics	3.10%
PAHC Phibro Animal Health	50.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMPH Amphastar Pharmaceuticals	2,028	46.49 million	33.71 million	Optionable
LRMR Larimar Therapeutics	30	82.78 million	79.05 million	Optionable
NTLA Intellia Therapeutics	600	107.35 million	104.02 million	Optionable
PAHC Phibro Animal Health	1,940	40.53 million	20.24 million	Optionable

LRMR, PAHC, NTLA, and AMPH Headlines

Recent News About These Companies

Independent Advisor Alliance Takes $577,000 Position in Phibro Animal Health Corporation (NASDAQ:PAHC)

August 16 at 4:29 AM | marketbeat.com

Phibro Animal Health Corporation (NASDAQ:PAHC) Shares Sold by Mackenzie Financial Corp

August 11, 2025 | marketbeat.com

Phibro Animal Health Corp. Financials | PAHC | Barron's

August 10, 2025 | barrons.com

Equities Analysts Offer Predictions for PAHC FY2026 Earnings

August 10, 2025 | americanbankingnews.com

Phibro Animal Health Corporation (NASDAQ:PAHC) Receives Average Rating of "Reduce" from Analysts

August 10, 2025 | americanbankingnews.com

Zacks Research Has Strong Forecast for PAHC FY2026 Earnings

August 9, 2025 | marketbeat.com

Phibro Animal Health Corporation (NASDAQ:PAHC) Given Consensus Rating of "Reduce" by Brokerages

August 5, 2025 | marketbeat.com

PAHC vs. LMAT: Which Stock Should Value Investors Buy Now?

August 4, 2025 | zacks.com

Empirical Financial Services LLC d.b.a. Empirical Wealth Management Makes New Investment in Phibro Animal Health Corporation (NASDAQ:PAHC)

August 4, 2025 | marketbeat.com

15,477 Shares in Phibro Animal Health Corporation (NASDAQ:PAHC) Acquired by Universal Beteiligungs und Servicegesellschaft mbH

August 4, 2025 | marketbeat.com

KLP Kapitalforvaltning AS Has $90,000 Stake in Phibro Animal Health Corporation (NASDAQ:PAHC)

August 1, 2025 | marketbeat.com

Phibro Animal Health Corporation (NASDAQ:PAHC) to Issue $0.12 Quarterly Dividend

July 30, 2025 | marketbeat.com

Navellier & Associates Inc. Takes Position in Phibro Animal Health Corporation (NASDAQ:PAHC)

July 27, 2025 | marketbeat.com

Best Growth Stocks to Buy for July 23rd

July 23, 2025 | zacks.com

Best Value Stocks to Buy for July 23rd

July 23, 2025 | zacks.com

Hussman Strategic Advisors Inc. Grows Stock Holdings in Phibro Animal Health Corporation (NASDAQ:PAHC)

July 18, 2025 | marketbeat.com

Jackson Creek Investment Advisors LLC Makes New Investment in Phibro Animal Health Corporation (NASDAQ:PAHC)

July 18, 2025 | marketbeat.com

Pzena Investment Management LLC Has $15.46 Million Position in Phibro Animal Health Corporation (NASDAQ:PAHC)

July 18, 2025 | marketbeat.com

Phibro Animal Health Corporation (NASDAQ:PAHC) Stock Holdings Trimmed by Teacher Retirement System of Texas

July 18, 2025 | marketbeat.com

Should Value Investors Buy Phibro Animal Health (PAHC) Stock?

July 17, 2025 | zacks.com

Best Growth Stocks to Buy for July 17th

July 17, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LRMR, PAHC, NTLA, and AMPH Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

$29.83 -0.38 (-1.26%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$29.83 0.00 (0.00%)

As of 08/15/2025 07:19 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Larimar Therapeutics NASDAQ:LRMR

$4.01 -0.25 (-5.87%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$4.06 +0.05 (+1.35%)

As of 08/15/2025 07:40 PM Eastern

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Intellia Therapeutics NASDAQ:NTLA

$10.99 +0.09 (+0.83%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$11.00 +0.01 (+0.05%)

As of 08/15/2025 07:59 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Phibro Animal Health NASDAQ:PAHC

$30.67 +0.10 (+0.33%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$30.66 -0.01 (-0.03%)

As of 08/15/2025 05:36 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time